Article

Safety and transparency of pediatric drug trials.

Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
JAMA Pediatrics (Impact Factor: 4.25). 12/2009; 163(12):1080-6. DOI: 10.1001/archpediatrics.2009.229
Source: PubMed

ABSTRACT To quantify the frequency and type of new safety information arising from studies performed under the auspices of the Pediatric Exclusivity Program, to describe the dissemination of these findings in the peer-reviewed literature and compare this with the US Food and Drug Administration (FDA) review, and to describe their effect on pediatric labeling.
Cohort study of the 365 trials performed for 153 drugs.
The Pediatric Exclusivity incentive from December 1997 through September 2007.
Food and Drug Administration publicly available records and peer-reviewed literature retrievable by MEDLINE search. Main Exposures New safety findings obtained from the trials completed for exclusivity.
Concordance of the information highlighted in the peer-reviewed article abstracts with the information in the FDA labeling and drug reviews.
There were 137 labeling changes; we evaluated 129 of these (the 8 selective serotonin reuptake inhibitors were excluded from review). Thirty-three products (26%) had pediatric safety information added to the labeling. Of these, 12 products had neuropsychiatric safety findings and 21 had other important safety findings. Only 16 of 33 of these trials (48%) were reported in the peer-reviewed literature; however, 7 of 16 focused on findings substantively different from those highlighted in the FDA reviews and labeling changes.
Medication adverse events in children often differ from those in adults, particularly those that are neuropsychiatric in nature. Labeling changes for pediatric use demonstrate that pediatric drug studies provide valuable and unique safety data that can guide the use of these drugs in children. Unfortunately, most of these articles are not published, and almost half of the published articles focus their attention away from the crucial safety data.

0 Bookmarks
 · 
132 Views
  • Biocontrol Science and Technology 12/2014; 14(12):14-15. DOI:10.1080/15265161.2014.964874 · 0.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Children deserve medicines that are adapted to their needs. The need to include children in drug development has been recognised increasingly over the past few decades. Legal and regulatory frameworks are well established in the EU and US. The amount of work done to study medicines for children is significantly greater than it was 10years go. Proof-of-concept has been demonstrated for all segments of the paediatric drug development pipeline. It is now time to examine how the practice of developing medicines for children has evolved within those frameworks and to determine how that work should be generalised. This review describes the development of medicines for children and critically appraises the work that has been done within those frameworks. Significant effort is needed to realize the potential provided by the current regulatory framework. Using the work programme of the Global Research in Paediatrics (GRiP) Network of Excellence as a template we outline current work and future growing points.
    Advanced drug delivery reviews 06/2014; 73. DOI:10.1016/j.addr.2014.02.003 · 11.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Globally there are numerous impediments, both logistical, regulatory and more recently global drug shortages, hindering pediatric access to therapeutic drugs of all types. Efforts to reduce barriers are ongoing and are especially important in low and middle income countries and for children requiring treatment of conditions such as those encountered in pediatric oncology characterized by the risk of life threatening treatment failures. Progress has been made through the efforts of the World Health Organization and regulators in the US and Europe to encourage the development of therapeutic agents for use in pediatrics and measures taken have fostered the availability of stronger pediatric data to guide therapeutic decisions. Nonetheless, pharmaceuticals remain a global commodity, subject to regulation by the World Trade Organization and this has often had detrimental effects in low and middle income countries. This article emphasizes the need for closer international collaboration to address the barriers currently impeding access to antineoplastic and supportive care medicines for children. Pediatr Blood Cancer © 2014 Wiley Periodicals, Inc.
    Pediatric Blood & Cancer 04/2014; 61(8). DOI:10.1002/pbc.25049 · 2.35 Impact Factor

Full-text (2 Sources)

Download
63 Downloads
Available from
May 22, 2014